Aclarion Inc., a healthcare technology firm specializing in biomarker-driven augmented intelligence for diagnosing chronic low back pain, revealed a comprehensive update on its progress as it approaches 2026. The company highlighted sustained commercial growth, advancements in clinical validation, and a reinforced financial position supporting continued market expansion.
Advances in Commercial Deployment and Market Growth
Throughout 2025, Aclarion experienced notable traction with its proprietary diagnostic platform, Nociscan, which integrates artificial intelligence to enhance the detection of issues related to chronic low back pain. Data indicates a 69% increase in annual scan volumes compared to the previous year, reflecting heightened clinical adoption. In the fourth quarter alone, scan volumes more than doubled, rising 114% year-over-year.
This growth streak represents the third consecutive quarter of consistent expansion and involves utilization across key geographic areas including the United States, United Kingdom, and select European regions. Furthermore, the company successfully integrated nine new imaging centers into its network and expanded its user base by onboarding 22 additional physician users in 2025. Alongside these operational enhancements, Aclarion fortified its commercial and executive teams, primarily within the U.S. and U.K. markets, preparing the infrastructure for broader distribution and engagement.
Clinical Evidence and Product Development Progress
Reinforcing the platform’s clinical credibility, Aclarion advanced ongoing research initiatives underpinning Nociscan’s effectiveness and economic value proposition. The CLARITY clinical trial launched in 2025 with active involvement from seven clinical sites, signifying pivotal groundwork for future commercial scaling.
Complementing trial activities, a published cost-effectiveness analysis compared Nociscan favorably against conventional provocative discography. According to findings reported in ClinicoEconomics and Outcomes Research, Nociscan demonstrated superior clinical effectiveness and reduced costs, generating an average per-patient saving of $1,712 and enhancing surgical success rates by 10%. Additional evidence, including real-world data and a technical overview of Nociscan, appeared in the International Journal of Spine Surgery, further validating the platform's clinical value.
Looking ahead, the company aims to enroll approximately one quarter of the targeted patients for the CLARITY study by the end of the second quarter of 2026. An interim internal data analysis is anticipated by the third quarter to assess ongoing progress and inform subsequent development stages.
Financial Health and Forward Outlook
From a financial perspective, Aclarion concluded 2025 with cash reserves totaling $12.0 million and maintained a debt-free balance sheet. This strong liquidity profile extends the company's operational runway well into the first half of 2027, offering flexibility to support clinical and commercial initiatives. Notably, the firm secured in excess of $22.0 million through equity financing during the past year, augmenting its capital base.
CEO Brent Ness commented on the company's trajectory, emphasizing satisfaction with Aclarion’s enhanced financial standing, expanding clinical foothold, and progress advancing Nociscan toward wider adoption across key target markets.
Market Reaction
Following these updates, Aclarion’s stock price surged significantly in Thursday premarket trading, climbing 55.13% to reach $8.92 per share according to real-time market data. This sharp rise reflects investor confidence buoyed by operational momentum, validated clinical results, and stable financial positioning as the company progresses.